Elucidating the Impact of Red Blood Cell Membrane Components on Melittin-Induced Pore Formation with Molecular Dynamics Simulations
The Journal of Physical Chemistry B · 2025
DOI: 10.1021/acs.jpcb.5c04289 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Physical Chemistry B, 2025. Verfasst von Joshua D Richardson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States. Hauptthemen laut MEDLINE: Melitten, Molecular Dynamics Simulation, Erythrocyte Membrane. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Division of Materials Research.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.
- Department of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.
ORCID-Profile: Reid C Van Lehn
Förderung
- Division of Materials Research
Zitieren
APA
Richardson, J. D., & Van Lehn, R. C. (2025). Elucidating the Impact of Red Blood Cell Membrane Components on Melittin-Induced Pore Formation with Molecular Dynamics Simulations. The Journal of Physical Chemistry B. https://doi.org/10.1021/acs.jpcb.5c04289
Vancouver
Richardson JD, Van Lehn RC. Elucidating the Impact of Red Blood Cell Membrane Components on Melittin-Induced Pore Formation with Molecular Dynamics Simulations. The Journal of Physical Chemistry B. 2025. doi:10.1021/acs.jpcb.5c04289
BibTeX
@article{Richardson2025,
author = {Richardson, Joshua D and Van Lehn, Reid C},
title = {Elucidating the Impact of Red Blood Cell Membrane Components on Melittin-Induced Pore Formation with Molecular Dynamics Simulations},
journal = {The Journal of Physical Chemistry B},
year = {2025},
doi = {10.1021/acs.jpcb.5c04289}
}
EUVIMED